Andrew Ullmann and Michael Moore  For six decades, respiratory syncytial virus (RSV) in infants was a public health problem without a solution.  According to the European Centre for Disease Prevention and Control (ECDC), an estimated 250,000 children under five are hospitalised each year across Europe due to RSV infection, overwhelming paediatric wards each winter, and […] Continue reading ->
Final talks on the Pathogen Access and Benefit-Sharing (PABS) system, the last outstanding piece of the Pandemic Agreement, are being held in Geneva this week. The Pandemic Agreement, being negotiated in Geneva, emerged to address the unacceptable inequities that defined the COVID-19 global health disaster. During this pandemic, delayed and inequitable access to vaccines may […] Continue reading ->
The European Commission intends to significantly cut its contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria, ending a decades-long trend of increasing contributions to the multilateral health organisation. According to research by Health Policy Watch, the Commission plans to pledge €700 million over a four-year span from 2026 to 2029 at the […] Continue reading ->
A stark debate over who owns the data in the future of AI and digital health emerged at the World Health Organization (WHO) Executive Board on Wednesday. Low and middle-income countries warned that the rapid deployment of new technologies risks accelerating data extraction and increasing inequality, cautioning that – without strict AI governance, sustainable financing […] Continue reading ->
A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading ->
STRASBOURG – The European Parliament backed the EU’s Critical Medicines Act (CMA) on Tuesday in a decisive move to secure Europe’s pharmaceutical supply chains from geopolitical shocks. With an overwhelming majority of 503 votes in favour, 57 against, and 108 abstentions, MEPs endorsed a sweeping industrial policy designed to re-shore the production of active ingredients […] Continue reading ->
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly established new AI principles in drug development to reduce regulatory divergence between the major markets of the European Union and the United States. Industry associations have applauded the landmark accord, as it strengthens harmonisation across the regions – but emphasise […] Continue reading ->